Bivision Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel targeted radiopharmaceuticals to address significant unmet medical needs.
Bivision has a diversified R&D pipeline cross different stage of drug discovery and development process. Its lead drug candidate JH02, a Lutetium-177 labeled small molecule ligand targeting Prostate Specific Membrane Antigen (PSMA) for the treatment of patients with metastatic castration resistant prostate cancer (mCRPC) has been approved by both FDA and CDE and currently is under Phase I/II clinical trial. Since inception, Bivision has built a proprietary technology platform which enables its drug R&D programs to be advanced to clinical stage much fast. Bivision will strive to become a patient-oriented biotech company committed to provide patients with better radiopharmaceuticals which allow more patients to have a better quality of life.
JH002
Therapy
Prostate Cancer
Peptides
JH003
JH004
Diagnostic
Therapy
Solid Tumor
Peptides/small molecules
N001
N002
Diagnostic
Therapy
Solid Tumor
Peptides/small molecules
